Alkermes (ALKS) Income from Discontinued Operations (2023 - 2024)
Alkermes' (ALKS) quarterly Income from Discontinued Operations came in at 354000.0 in Q4 2024, down 94.88% year-on-year from 6914000.0 in Q1 2024, and up 628.36% on a QoQ basis from 67000.0 in Q3 2024.
Alkermes (ALKS) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Alkermes (ALKS) has 2 years of Income from Discontinued Operations data on file, last reported at 354000.0 in Q4 2024.
- On a quarterly basis, Income from Discontinued Operations fell 94.88% year-over-year to 354000.0 in Q4 2024; TTM through Dec 2024 was 722000.0, a N/A change from a year earlier, with the FY2024 full-year figure at 722000.0, up 48.54% from the prior year.
- Income from Discontinued Operations for Q4 2024 stood at 354000.0, up from 67000.0 in the prior quarter.
- Over the last five years, Income from Discontinued Operations for ALKS reached as high as 6914000.0 in Q4 2023 and fell as low as 1550000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 354,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Jun 30, 2024 | -613,000.00 |
| Mar 31, 2024 | -396,000.00 |
| Dec 31, 2023 | 6.91 Mn |
| Sep 30, 2023 | -1.55 Mn |
| Jun 30, 2023 | -40,000.00 |